Actively Recruiting

Phase 2
Age: 18Years +
All Genders
NCT05623111

Perineural Injections of Incobotulinumtoxin-A for Diabetic Neuropathic Pain of the Lower Extremities

Led by Rigshospitalet, Denmark · Updated on 2025-12-10

80

Participants Needed

1

Research Sites

226 weeks

Total Duration

On this page

Sponsors

R

Rigshospitalet, Denmark

Lead Sponsor

M

Merz Pharmaceuticals GmbH

Collaborating Sponsor

AI-Summary

What this Trial Is About

The goal of this clinical trial is to test perineural injections (injections around a nerve) of incobotulinumtoxin-A in participants with diabetic nerve pain of the feet and lower legs. The main questions it aims to answer are: * Is the treatment safe and effective? * Does the treatment affect participants quality of life, depression, physical activity, daily life, and sensation? Participants will be treated every 12 weeks, for a total of 24 weeks, with either incobotulinumtoxin-A or a placebo.

CONDITIONS

Official Title

Perineural Injections of Incobotulinumtoxin-A for Diabetic Neuropathic Pain of the Lower Extremities

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Are 18 years or older
  • Are diagnosed with diabetes type I or II
  • Score 3 or above on the Doleur Neuropathique 4 interview section
  • Have lower extremity pain that is their dominant overall pain
  • Have pain rated at least 4 out of 10 on the NRS scale in both legs (average over past 7 days)
  • Have pain present roughly symmetrically in both feet
  • Have had this pain for at least 6 months
  • Show sensory deficits and/or allodynia or hyperalgesia in the painful area consistent with probable chronic neuropathic pain
  • Are on a stable analgesic treatment regimen for at least 1 month prior to inclusion and during the study
  • Are using an approved, safe contraceptive if premenopausal
  • Speak, read, and understand Danish
Not Eligible

You will not qualify if you...

  • Have a known allergy or hypersensitivity to Botulinum toxin A
  • Have been treated with Botulinum toxin in the last 6 months
  • Are diagnosed with myasthenia, Eaton-Lambert syndrome, or amyotrophic lateral sclerosis
  • Have a known malignant condition
  • Have an ongoing infection in the injection area
  • Expect to change pain medication during the study
  • Have used topical agents like capsaicin or lidocaine in affected areas within 3 months prior to inclusion
  • Are diagnosed with other causes of neuropathic pain or chronic lower extremity pain such as spinal stenosis, claudication, previous trauma or nerve injury, or cancer-related pain
  • Have a psychiatric condition affecting study participation
  • Are active abusers of alcohol or illegal substances
  • Are using or receiving cannabis treatment
  • Are pregnant or planning pregnancy during the study
  • Score more than 12 on the Charlson Comorbidity Index

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Rigshospitalet Glostrup

Glostrup Municipality, Denmark, 2600

Actively Recruiting

Loading map...

Research Team

M

Marc Klee Olsen, MD

CONTACT

T

Trine Thomsen, MsC

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

TRIPLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here